- My News
- All News
- Most Popular
Digital diabetes management company Glooko announced Thursday that it has appointed Zach Henderson as chief commercial officer and Komathi Stem as chief operating officer. CEO Russ Johannesson said the new hires are joining Glooko "as we expand our offerings to help the global healthcare ecosystem better understand and manage diabetes and support healthcare providers managing their patient populations using our data, analytics and clinical research solutions."
Prior to Glooko, Henderson served as vice president of strategy, alliances and data sourcing at LexisNexis Health Care and Elsevier, and before that held a range of senior commercial leadership positions at healthcare data and analytics companies. In his new role, he will oversee all commercial efforts at Glooko, including the company's work with strategic partners and revenue generation initiatives. "Glooko is integrated with more diabetes and health devices than any other platform in the world, creating an opportunity to provide extensive insights…I'm excited to be joining the Glooko team as it transitions to its next phase of growth," Henderson remarked.
Meanwhile, Stem has held leadership roles at Science 37, Genentech, AstraZeneca, Amgen and Eli Lilly, and was most recently CEO of health data collection and analytics company monARC Bionetworks. As chief operating officer at Glooko, she will be responsible for product development, clinical research and customer support. The latest appointments follow the hiring of Stephen Lien as chief financial officer last July.
Glooko emerged in its present form following its 2016 merger with Diasend to "accelerate the overarching mission to make diabetes management easier worldwide." It has a number of partnerships, including with Novo Nordisk to jointly develop digital health solutions for patients with diabetes, as well as with Ascensia Diabetes Care, Dexcom and Senseonics. In 2018, the FDA cleared Glooko's mobile insulin dosing system for the titration of long-acting insulin for patients with type 2 diabetes.
Did you like this article?